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The Ability of β-Cells to Compensate for Insulin Resistance is 
Restored with a Reduction in Excess Growth Hormone in Korean 
Acromegalic Patients
The aim of this study was to assess the prevalence of diabetes and to study the effects of 
excess growth hormone (GH) on insulin sensitivity and β-cell function in Korean 
acromegalic patients. One hundred and eighty-four acromegalic patients were analyzed to 
assess the prevalence of diabetes, and 52 naïve acromegalic patients were enrolled in order 
to analyze insulin sensitivity and insulin secretion. Patients underwent a 75 g oral glucose 
tolerance test with measurements of GH, glucose, insulin, and C-peptide levels. The insulin 
sensitivity index and β-cell function index were calculated and compared according to 
glucose status. Changes in the insulin sensitivity index and β-cell function index were 
evaluated one to two months after surgery. Of the 184 patients, 17.4% were in the 
normal glucose tolerance (NGT) group, 45.1% were in the pre-diabetic group and 37.5% 
were in the diabetic group. The insulin sensitivity index (ISI0,120) was significantly higher and 
the HOMA-IR was lower in the NGT compared to the diabetic group (P = 0.001 and 
P = 0.037, respectively). The ISI0,120 and disposition index were significantly improved after 
tumor resection. Our findings suggest that both insulin sensitivity and β-cell function are 
improved by tumor resection in acromegalic patients.
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INTRODUCTION
Glucose homeostasis abnormalities such as impaired glucose 
intolerance (IGT) and diabetes mellitus frequently affect acro-
megalic patients. The prevalence of IGT or diabetes mellitus dif-
fers widely between studies due to differences in patient num-
bers and ethnicity (1-3). 
  Impaired glucose metabolism in acromegalic patients is fre-
quently associated with hyperinsulinemia (4, 5). It has been sug-
gested that impaired glucose metabolism is mediated by growth 
hormone (GH)-induced insulin resistance. Several studies have 
suggested that insulin resistance contributes to abnormal glu-
cose tolerance in acromegalic patients (6-8), but Kasayama et 
al. (9) reported that impaired β-cell function is important in de-
termining the glucose tolerance status in acromegalic patients, 
and Kinoshita et al. (10) reported that once β-cell function is im-
paired, abnormal glucose metabolism persists even after pa-
tients have been cured of acromegaly. Therefore, both insulin 
resistance and pancreatic β-cell dysfunction appear to be in-
volved in the pathogenesis of glucose homeostasis abnormali-
ties in acromegalic patients. Furthermore, some studies have 
reported a direct correlation between plasma GH levels and the 
degree of glucose intolerance (11, 12).
  The aim of this study was to assess the prevalence of diabetes, 
impaired fasting glucose (IFG) and IGT in Korean patients with 
acromegaly and to study the changes in insulin sensitivity and 
β-cell function index with a reduction in excess GH after tumor 
resection.
MATERIALS AND METHODS
Our study included 184 acromegalic patients who had been di-
agnosed with acromegaly at Samsung Medical Center between 
1996 and 2009. The prevalence of diabetes was assessed in these 
patients. Patients were classified as having a normal glucose 
tolerance (NGT, fasting plasma glucose [FPG] < 100 mg/dL and 
2-hr glucose post-prandial glucose [PPG] < 140 mg/dL), IFG 
(FPG 100-125 mg/dL), IGT (PPG 140-199 mg/dL) and diabetes 
(FPG ≥ 140 mg/dL and/or PPG ≥ 200 mg/dL) according to the 
American Diabetes Association diagnostic criteria (13). 
  Diagnosis of active acromegaly was based on characteristic 
clinical findings, plasma GH elevated above 1 μg/L during the Kim SK, et al.  •  Glucose Intolerance in Acromegaly
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75 g oral glucose tolerance test (OGTT) and plasma insulin-like 
growth factor-1 (IGF-1) elevated above the normal range for age 
and sex. During the OGTT, glucose and GH levels were mea-
sured before ingestion and at 30, 60, 90, and 120 min thereafter, 
and insulin and C-peptide levels were measured before inges-
tion and then at 30 and 120 min. All measurements were per-
formed prior to any therapeutic intervention. Completely cured 
acromegaly was defined as a GH less than 1 μg/L during the 
OGTT. Disease duration was evaluated by patient interview.
  Several models were used to estimate insulin sensitivity and 
secretion using plasma glucose and insulin concentrations mea-
sured during the OGTT. For basal insulin secretion and insulin 
resistance, the homeostasis model assessment of β-cell function 
(HOMA-β) and insulin resistance (HOMA-IR) were calculated 
(15). ISI0,120 is a formula for the insulin sensitivity index (ISI), and 
was calculated as follows: {75,000 + (glucose0min [mg/dL] - glu-
cose120min [mg/dL]) × 0.19 × body weight (kg)/[120 × log(insu- 
lin0min [μU/mL] + insulin120min [μU/mL])/2 × (glucose0min [mg/
dL] + glucose120min [mg/dL)/2]} (16). The disposition index (DI) 
was calculated as the insulinogenic index multiplied by ISI0,120. 
The DI has been proposed as a measurement of the ability of 
β-cells to compensate for insulin resistance (17). Lower DI val-
ues indicate an inability of β-cells to secrete enough insulin at 
that particular level of insulin resistance. We also calculated the 
first and second phase of insulin secretion. First-phase insulin 
secretion = 1,283 + 1.829 × insulin30min (pM/L) - 138.7 × glu-
cose0min (mM/L) + 3.772 × insulin0min (pM/L) and second-phase 
insulin secretion = 287 + 0.4164 × insulin30min (pM/L)-26.07 ×  
glucose30min (mM/L) + 0.9226 × insulin0min (pM/L) (18).
  Of the 184 acromegalic patients, 35 patients with known dia-
betes and 44 patients lacking laboratory data for insulin and C-
peptides were excluded from the analysis of insulin sensitivity 
and β-cell function. Of the 105 acromegalic patients, 80 patients 
underwent the 75 g OGTT one to two months after the trans-
sphenoidal surgery. Fifty-two patients were included in the fi-
nal analysis to assess changes in insulin sensitivity and β-cell 
function after tumor resection. 
Statistics
Data are presented as the mean ± standard deviation (SD) or 
median (25th percentile to 75th percentile). A chi-square with 
Fisher’s exact test or the Kruskal-Wallis test was used to detect 
differences between the groups. Wilcoxon’s signed-rank test was 
used to assess changes after tumor resection and Spearman’s 
correlation analysis was used to assess correlations. Statistical 
analysis was performed using PASW 18.0 software (SPSS Inc., 
Chicago, IL, USA). For all statistical analyses, a P value  < 0.05 
(two-sided) was considered statistically significant.
Ethics statement
This study was approved by the institutional review board of Sam-
sung Medical Center (IRB No. 2011-04-040). Informed consent 
was exempted by the board.
RESULTS
Of the 184 acromegalic patients, 69 patients (37.5%) were dia-
betics (including those who were previously known diabetics), 
43 patients (23.4%) were IGT, 16 patients (8.7%) were IFG, 23 
patients (13.0%) were combined IGT and IFG, and 32 patients 
(17.4%) were NGT. 
  We re-categorized the 184 patients into three groups (NGT, 
pre-diabetic [IFG + IGT] and diabetic). The clinical characteris-
tics of all 184 patients are shown in Table 1. The diabetic patients 
were significantly older than the pre-diabetic and the NGT pa-
tients.
  Fifty-two patients were included for the final analysis to assess 
changes in insulin sensitivity and β-cell function after tumor re-
section. Twelve patients (23.1%) were diabetic, 27 patients (51.9%) 
were pre-diabetic and 13 patients (25.0%) were classified as hav-
ing a NGT. The median age was 40 yr (30-51). The median basal 
GH, nadir GH, and IGF-1 levels were 16.9 μg/L (9.0-26.9), 13.0 
μg/L (5.7-26.9) and 1,051.8 (851.9-1,353.9), respectively. Body 
mass index (BMI) was 26.1 ± 2.6 kg/m
2.
  Serum glucose levels after the ingestion of 75 g of glucose were 
significantly higher in patients with diabetes (P = 0.001) (Fig. 1). 
Table 1. Clinical characteristics of the normal glucose tolerance, pre-diabetic and diabetic groups among 184 acromegalic patients
Parameters NGT (n = 32) Pre-diabetic (n = 83) Diabetic (n = 69) P value
Age (yr)   37.7 ± 12.7   41.7 ± 11.9    48.9 ± 11.2* 0.001
Sex (male/female) 12/20 46/37 34/35 0.218
Body mass index (kg/m
2) 25.1 ± 2.5 25.8 ± 2.9 25.7 ± 2.9 0.456
Median disease duration (yr) 1.0 (1.0-4.0) 2.0 (1.0-5.0) 3.0 (1.0-8.0) 0.110
Hypertension (No. [%])   5 (15.6%) 17 (20.5%) 20 (29.0%) 0.287
Macroadenoma (No. [%]) 27 (84.4%) 70 (84.3%) 61 (88.4%) 0.755
Family history of diabetes (No. [%])   6 (18.8%) 11 (13.3%) 16 (23.2%) 0.275
Basal GH (µg/L)   17.2 (10.5-36.9) 16.6 (7.8-22.0) 19.2 (6.9-45.6) 0.272
Nadir GH (µg/L) 13.1 (6.4-29.4) 11.5 (4.9-18.5) 16.6 (5.7-36.0) 0.204
IGF-1 963.7 (697.6-1339.9) 935.8 (742.3-1245.9) 815.0 (647.1-1143.2) 0.320
*Statistically significant between NGT and diabetic and between pre-diabetic and diabetic. NGT, normal glucose tolerance; IGF-1, insulin-like growth factor-1.Kim SK, et al.  •  Glucose Intolerance in Acromegaly
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Serum C-peptide levels at 0 min of the OGTT were higher in the 
diabetic group compared to the pre-diabetic group (P = 0.028), 
and serum C-peptide levels at 120 min of the OGTT were higher 
in the diabetic group when compared to the NGT group (P =  
0.023). There were no significant differences in family history of 
diabetes, sex or the presence of hypertension among the three 
groups (Table 2). There were also no significant differences in 
basal GH, nadir GH, or IGF-1 between the three groups. 
  Hypocortisolism was present in 28 (64.3%) patients before 
tumor resection and in 15 (28.8%) patients after tumor resec-
tion. Hypothyroidism was present in three (5.8%) patients be-
fore tumor resection and in one (1.9%) patient afterwards. The 
prevalence of hypocortisolism and hypothyroidism was not sig-
nificantly different between groups.
Insulin sensitivity index and β-cell function index 
according to glucose status
The insulin sensitivity index, ISI0,120, was significantly higher and 
HOMA-IR was significantly lower in the NGT group compared 
to the pre-diabetic and diabetic groups (Fig. 2). HOMA-β did 
not differ significantly between the groups (P = 0.116). The first-
phase insulin secretion was significantly higher in the NGT group 
compared to the pre-diabetic and diabetic groups (Fig. 2). The 
second-phase insulin secretion was not different among the 
Table 2. Clinical characteristics of the normal glucose tolerance, pre-diabetic and diabetic groups among 52 acromegalic patients 
Parameters NGT (n = 13) Pre-diabetic (n = 27) Diabetic (n = 12) P value
Age (yr)   34.7 ± 14.3   41.7 ± 12.9   44.9 ± 11.9 0.117
Sex (male/female) 4/9 10/17 5/7 0.930
Body mass index (kg/m
2) 25.9 ± 2.0 26.0 ± 2.6 26.6 ± 3.2 0.866
Median disease duration (yr) 1.0 (1.0-6.5) 4.0 (1.0-5.0)  7.3 (1.0-8.0) 0.360
Hypertension (No. [%])   3 (23.1%)   4 (14.8%)    5 (41.7%) 0.153
Macroadenoma (No. [%]) 11 (84.6%) 24 (88.9%) 12 (100%) 0.582
Family history of diabetes (No. [%])   4 (30.8%)   3 (11.1%)    2 (16.7%) 0.304
Basal GH (µg/L) 17.3 (8.1-39.6) 13.3 (7.8-20.4) 18.5 (11.9-70.9) 0.184
Nadir GH (µg/L) 13.1 (5.3-30.7) 10.5 (4.9-18.5) 16.8 (10.9-53.6) 0.167
IGF-1 1,331.0 (902.4-1,752.5) 1,020.9 (849.3-1,228.5) 1,071.9 (829.1-1,143.5) 0.260
NGT, normal glucose tolerance; IGF-1, insulin-like growth factor-1.
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Fig. 1. Results of the 75 g oral glucose tolerance test according to glucose status 
for 52 acromegalic patients.
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three groups (P = 0.062). The DI also was markedly decreased 
in the diabetic group as compared to the NGT group (P = 0.009). 
  The nadir GH, basal GH and IGF-1 levels did not correlate with 
the DI, HOMA-β, or the first or second phase insulin secretion 
indexes. The IGF-1 level correlated with HOMA-IR (r = 0.416, 
P = 0.002), the basal insulin level (r = 0.406, P = 0.003), and the 
basal C-peptide level (r = 0.381, P = 0.005). HOMA-IR was posi-
tively correlated with HOMA-β (r = 0.369, P = 0.007), and the 
first and second phases of insulin secretion (r = 0.359, P = 0.014 
and r = 0.383, P = 0.009, respectively).
Effect of surgery on glucose status, insulin sensitivity 
index and β-cell function
Normalization of excess GH (< 1 μg/L) occurred in 26 patients 
(50%). There were significant improvements in the average lev-
els of basal GH (16.9 [9.0-26.9] vs 1.8 [0.4-4.3], P = 0.001), nadir 
GH (13.0 [5.7-26.9] vs 0.6 [0.1-2.4], P = 0.001) and IGF-1 (1,051.8 
[851.9-1,353.9] vs 423.8 [269.3-636.0], P = 0.001) after tumor re-
section.
  Of the 13 NGT patients, 10 retained a NGT status and 3 pa-
tients became pre-diabetic after the surgery. Of the 27 pre-dia-
betic patients, 18 patients achieved a NGT status, while the rest 
9 remained in a pre-diabetic state after the surgery. Of the 12 di-
abetes patients, 7 patients attained a NGT status, 4 patients be-
came pre-diabetic and 1 patient remained diabetic after the sur-
gery. With the exception of the three NGT patients who were re-
classified as being pre-diabetic after the surgery, all glucose levels 
at 0, 30, 60, 90, and 120 min were significantly improved after tu-
mor resection, regardless of the extent of tumor resection, glu-
cose concentration or the presence of other hormone deficien-
cies (Fig. 3). We noted significant improvements in HOMA-IR, 
ISI0,120 and DI one to two months after surgery. There were sig-
nificant decreases in the first-phase insulin secretion (1,315.9 
[868.8-2,258.8] vs 1,114.5 [839.0-2,258.8] P = 0.007) and second-
phase insulin secretion indexes (354.2 [251.0-568.1] vs 301.2 
[232.3-408.5] P = 0.003). However, there were no significant im-
provements in HOMA-β after the surgery (Fig. 3). 
  The improvements in HOMA-IR, ISI0,120 and DI occurred in 
both the completely and incompletely cured groups. The group 
of patients that still had a nadir GH level elevated above 1 μg/L 
also showed improvements in HOMA-IR [3.9 (2.7-4.9) vs 2.0 (1.2-
3.1), P = 0.001], ISI0,120 [0.31 (0.12-0.61) vs 1.48 (0.89-2.43), P =  
0.001] and DI [0.23 (0.06-0.45) vs 1.77 (1.40-2.09), P = 0.001]after 
the surgery.
DISCUSSION
Of the 184 acromegalic patients in this study, only 17.4% of pa-
tients had a normal glucose status. The prevalence of diabetes 
was 37.5%, including those who were previously known diabet-
ic patients, which is much higher than that seen in the general 
Korean population (9.1%) (19). A previous study reported that 
the prevalence of diabetes and IGT varied widely from 19% to 
56% and from 16% to 46%, respectively (1, 3). This study sample 
had a higher prevalence of glucose intolerance than that reported 
in previous studies (12, 20), which could be partly attributed to 
1
s
t
 
p
h
a
s
e
 
i
n
s
u
l
i
n
 
s
e
c
r
e
t
i
o
n
D
i
s
p
o
s
i
t
i
o
n
 
i
n
d
e
x
P = 0.022 P = 0.042
P = 0.004 P = 0.007
P = NS
P = NS
  NGT  Pre-diabetes  Diabetes   NGT  Pre-diabetes  Diabetes
3,000
2,000
1,000
0
0.8
0.6
0.4
0.2
0.0
D E
I
S
I
0
,
1
2
0
H
O
M
A
-
I
R
H
O
M
A
-
β
 
c
e
l
l
 
f
u
n
c
t
i
o
n
 
(
%
) P = 0.006
P = NS
P = NS
P = 0.029 P = 0.014 P = NS
P = NS P = 0.022 P = NS
  NGT  Pre-diabetes  Diabetes   NGT  Pre-diabetes  Diabetes   NGT  Pre-diabetes  Diabetes
3
2
1
0
10
8
6
4
2
0
300
200
100
0
A B C
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the difference in diagnostic criteria used in our study (NGT, FPG 
< 100 mg/dL) compared to previous studies (NGT, FPG < 110 
mg/dL) (9, 11). 
  The clinical risk factors for glucose intolerance in acromegaly 
are known to be a prolonged duration of disease, a family histo-
ry of diabetes, age and the presence of macroadenoma (1, 2). Age 
differed significantly between the diabetic and pre-diabetic or 
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NGT groups in our study (Table 1). However, other factors did 
not significantly affect glucose intolerance.
  We assessed insulin sensitivity and β-cell function according 
to glucose status. Kasayama et al. (9) reported that insulin sen-
sitivity is reduced to a similar extent in acromegalic patients re-
gardless of glucose status, and that impaired β-cell function de-
termined the glucose status in acromegalic patients. Kinoshita Kim SK, et al.  •  Glucose Intolerance in Acromegaly
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et al. (10) also reported that the parameters of insulin resistance 
did not differ significantly according to glucose status. However, 
our study showed that both insulin sensitivity and β-cell func-
tion, as measured by ISI0,120 and the first phase of insulin secre-
tion index, were lower in the diabetic patients compared to the 
NGT patients. This suggests that impaired β-cell function, with 
reduced insulin sensitivity, occurs during the development of 
glucose intolerance from NGT to hyperglycemia in acromegalic 
patients. In the pre-diabetic state, there was a significant decrease 
in the ISI0,120 and the DI. However, the HOMA-IR and HOMA-β 
did not differ between the NGT and pre-diabetic groups. Fur-
thermore, HOMA-β was not significantly different between the 
NGT and diabetic groups. This suggests that the ISI0,120 and the 
first-phase insulin secretion index are more useful methods than 
HOMA analysis in evaluating insulin sensitivity and β-cell func-
tion in acromegalic patients (Fig. 2).  
  Of the 52 patients, 26 (50%) achieved normalization of GH 
and IGF-1 levels after surgery. There were no differences in the 
levels of GH and IGF-1 according to glucose status, which is con-
sistent with the findings of previous studies (2, 9). However, IGF-1 
levels were correlated with HOMA-IR and fasting insulin, simi-
lar to what was shown in previous studies (12, 21).
  One to two months after the trans-sphenoidal surgery, patients 
showed significant improvements in serum nadir GH and IGF-1 
levels, as well as in ISI0,120, HOMA-IR, and the DI. Wasada et al. 
(7) and Moller et al. (8) also reported that insulin sensitivity im-
proved two to four months after surgery, and even within two 
weeks of the surgery. Insulin sensitivity improved in both the 
completely and incompletely cured groups in our study. Kinoshi-
ta et al. (10) reported that improving insulin resistance contrib-
utes to the restoration of normal glucose metabolism. They also 
reported that postoperative values of insulin resistance were 
similar between NGT and IGT/diabetic groups, and that HOMA-β 
was significantly lower in the IGT/diabetic group. 
  In most of our patients, all glucose levels during the OGTT 
were significantly improved after tumor resection, regardless of 
the extent of tumor resection, glucose concentration or the pres-
ence of other hormone deficiencies. These improvements can 
be explained by the improvements in both insulin resistance 
and β-cell function. The insulin secretion indexes, both first- and 
second-phase were decreased with improvements in insulin re-
sistance after tumor resection. However, the DI, which is a mea-
sure of pancreatic function, improved after tumor resection, sug-
gesting that not only insulin resistance, but also the ability of 
β-cells to compensate for particular level of insulin resistance 
improved after tumor resection. 
  There were still significant differences in the DI (2.02 ± 0.66 
vs 1.49 ± 0.46, P = 0.001) between patients who recovered NGT 
after the surgery (n = 28) and patients who retained a pre-dia-
betic/diabetic status after the surgery (n = 14), and there were 
no differences in HOMA-β, ISI0,120, or the first- or second-phase 
insulin secretion indexes among the groups (data not shown) 
contrary to the study by Kinoshita et al. (10).
  GH is known to stimulate the proliferation of pancreatic β- 
cells and enhances insulin secretion (22, 23). However, when 
there is an excess of GH, glucose intolerance develops. The ex-
act mechanism underlying a decreased insulin secretion index 
or increased insulin resistance is not fully understood in acro-
megalic patients. However, there have been several studies re-
garding the mechanism of increased insulin resistance in acro-
megalic patients. Hansen et al. reported that GH results in insu-
lin resistance by altering the function at the post-binding stage, 
and in vitro observations revealed that GH decreases insulin 
binding at high concentrations of insulin (24, 25). 
  This study is limited in that the analyses were done retrospec-
tively and only 52 patients were analyzed for the effects of surgery 
on insulin sensitivity and β-cell function. In addition, changes 
in insulin sensitivity and insulin secretion were not observed 
over the course of time. Thus, a longitudinal prospective study 
with long-term follow-up is required.
  In summary, both insulin sensitivity and β-cell function de-
creased in diabetic acromegalic patients. Insulin sensitivity and 
the functionality of the pancreas, as measure by the DI, improved 
after the tumor resection. Thus, we conclude that both insulin 
sensitivity and β-cell function are improved by a decrease in ex-
cess GH, which contribute to improvements in glucose status 
after tumor resection in acromegalic patients.
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